- Home
- AMGN vs GILD Comparison
AMGN vs GILD Comparison
Compare AMGN & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- GILD
- Stock Information
- Founded
- AMGN 1980
- GILD 1987
- Country
- AMGN United States
- GILD United States
- Employees
- AMGN N/A
- GILD N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMGN Health Care
- GILD Health Care
- Exchange
- AMGN Nasdaq
- GILD Nasdaq
- Market Cap
- AMGN 156.2B
- GILD 129.9B
- IPO Year
- AMGN N/A
- GILD 1992
- Fundamental
- Price
- AMGN $265.86
- GILD $96.91
- Analyst Decision
- AMGN Buy
- GILD Buy
- Analyst Count
- AMGN 19
- GILD 25
- Target Price
- AMGN $324.37
- GILD $109.00
- AVG Volume (30 Days)
- AMGN 2.7M
- GILD 8.7M
- Earning Date
- AMGN 05-01-2025
- GILD 04-24-2025
- Dividend Yield
- AMGN 3.58%
- GILD 3.26%
- EPS Growth
- AMGN 56.16
- GILD 1118.07
- EPS
- AMGN 10.94
- GILD 4.73
- Revenue
- AMGN $34,126,000,000.00
- GILD $28,735,000,000.00
- Revenue This Year
- AMGN $7.19
- GILD $1.88
- Revenue Next Year
- AMGN $2.37
- GILD $3.95
- P/E Ratio
- AMGN $24.29
- GILD $20.47
- Revenue Growth
- AMGN 15.56
- GILD 4.68
- 52 Week Low
- AMGN $253.30
- GILD $62.07
- 52 Week High
- AMGN $346.85
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- AMGN 34.80
- GILD 34.47
- Support Level
- AMGN $268.81
- GILD $95.30
- Resistance Level
- AMGN $291.61
- GILD $107.17
- Average True Range (ATR)
- AMGN 7.54
- GILD 3.66
- MACD
- AMGN -0.76
- GILD -0.73
- Stochastic Oscillator
- AMGN 0.76
- GILD 24.95
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).